Q-omics provides the consensus-scored LINC01138 profile across patient tissues and cancer cell-line models. LINC01138 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01138 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LINC01138 RNA expression shows 18,357 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where LINC01138 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01138 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01138 survival associations across molecular data types. LINC01138 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01138 RNA expression–survival associations across cancer types. High LINC01138 expression shows unfavorable associations in KIRC, LIHC and ACC, but favorable associations in SKCM, BLCA and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01138 RNA expression.
This table summarizes LINC01138 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01138. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01138 shows higher tumor expression in KIRC, COAD, LIHC, BLCA, HNSC and KIRP. The KIRC box plot shows higher LINC01138 RNA expression in tumor versus normal tissue (log2 FC = +0.867, t-test p < 0.001).
This table shows molecular features associated with LINC01138 in patient tissues and cancer cell lines. In patient samples, LINC01138 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
